Literature DB >> 30214551

Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Yu Yu1, Jiuwei Cui1.   

Abstract

Modulation of the tumor microenvironment is becoming an increasingly popular research topic in the field of immunotherapy, and studies regarding immune checkpoint blockades and cancer immunotherapy have pushed cancer immunotherapy to a climax. Simultaneously, the manipulation of the immune regulatory pathway can create an effective immunotherapy strategy; however, the tumor microenvironment serves an important role in suppressing the antitumor immunity by its significant heterogeneity. A number of patients with cancer do not have a good response to monotherapy approaches; therefore, combination strategies are required to achieve optimal therapeutic benefits. Targeting the tumor microenvironment may provide a novel strategy for immunotherapy, break down the resistance of conventional cancer therapy and produce the foundation for personalized precision medicine. The present review summarized the research regarding cancer immunotherapy from the perspective of how the tumor microenvironment affects the immune response, with the aim of proposing a novel strategy for cancer immunotherapy and combination therapy.

Entities:  

Keywords:  cancer immunotherapy; combination therapy; immune checkpoint blockade; tumor microenvironment

Year:  2018        PMID: 30214551      PMCID: PMC6126324          DOI: 10.3892/ol.2018.9219

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  93 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

Authors:  B Melichar; S Bracarda; V Matveev; B Alekseev; S Ivanov; A Zyryanov; R Janciauskiene; E Fernebro; P Mulders; S Osborne; S Jethwa; G Mickisch; M Gore; R J A van Moorselaar; M Staehler; N Magne; J Bellmunt
Journal:  Ann Oncol       Date:  2013-06-26       Impact factor: 32.976

Review 3.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies.

Authors:  Agnieszka Anna Rucki; Lei Zheng
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 4.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

5.  First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

Authors:  Gregory L Beatty; Peter J O'Dwyer; Jason Clark; Jack G Shi; Kevin J Bowman; Peggy A Scherle; Robert C Newton; Richard Schaub; Janet Maleski; Lance Leopold; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2017-01-04       Impact factor: 12.531

6.  Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

Authors:  Yingming Zhu; Yuanwei Zang; Fen Zhao; Zhenxiang Li; Jianbo Zhang; Liang Fang; Minghuan Li; Ligang Xing; Zhonghua Xu; Jinming Yu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

7.  Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.

Authors:  Chen Huang; Shile Sheng; Rui Li; Xiaoguang Sun; Jianju Liu; Gang Huang
Journal:  Oncol Rep       Date:  2014-12-08       Impact factor: 3.906

Review 8.  Interleukin-2: Biology, Design and Application.

Authors:  Natalia Arenas-Ramirez; Janine Woytschak; Onur Boyman
Journal:  Trends Immunol       Date:  2015-11-10       Impact factor: 16.687

9.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.

Authors:  Eddy W Yue; Richard Sparks; Padmaja Polam; Dilip Modi; Brent Douty; Brian Wayland; Brian Glass; Amy Takvorian; Joseph Glenn; Wenyu Zhu; Michael Bower; Xiangdong Liu; Lynn Leffet; Qian Wang; Kevin J Bowman; Michael J Hansbury; Min Wei; Yanlong Li; Richard Wynn; Timothy C Burn; Holly K Koblish; Jordan S Fridman; Tom Emm; Peggy A Scherle; Brian Metcalf; Andrew P Combs
Journal:  ACS Med Chem Lett       Date:  2017-03-06       Impact factor: 4.345

10.  A phase I study of indoximod in patients with advanced malignancies.

Authors:  Hatem H Soliman; Susan E Minton; Hyo Sook Han; Roohi Ismail-Khan; Anthony Neuger; Fatema Khambati; David Noyes; Richard Lush; Alberto A Chiappori; John D Roberts; Charles Link; Nicholas N Vahanian; Mario Mautino; Howard Streicher; Daniel M Sullivan; Scott J Antonia
Journal:  Oncotarget       Date:  2016-04-19
View more
  21 in total

1.  Health technology assessment with risk aversion in health.

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  J Health Econ       Date:  2020-06-06       Impact factor: 3.883

Review 2.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 3.  The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma.

Authors:  Shengnan Zhang; Mengjuan Li; Fangfang Yuan; Lin Chen; Ruihua Mi; Xudong Wei; Yongping Song; Qingsong Yin
Journal:  Cancer Cell Int       Date:  2019-10-22       Impact factor: 5.722

Review 4.  The future of microfluidics in immune checkpoint blockade.

Authors:  Jonathan Briones; Wilfred Espulgar; Shohei Koyama; Hyota Takamatsu; Eiichi Tamiya; Masato Saito
Journal:  Cancer Gene Ther       Date:  2020-10-27       Impact factor: 5.987

5.  Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.

Authors:  Mark A Perazella
Journal:  Kidney360       Date:  2020-02-11

6.  Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Jatuporn Sujjitjoon; Nunghathai Sawasdee; Naravat Poungvarin; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

7.  Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.

Authors:  Jasna Metovic; Laura Annaratone; Alessandra Linari; Simona Osella-Abate; Chiara Musuraca; Francesca Veneziano; Chiara Vignale; Luca Bertero; Paola Cassoni; Nicola Ratto; Alessandro Comandone; Giovanni Grignani; Raimondo Piana; Mauro Papotti
Journal:  Cancer Immunol Immunother       Date:  2020-05-06       Impact factor: 6.968

Review 8.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

Review 9.  Neuropilins in the Context of Tumor Vasculature.

Authors:  Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2019-02-01       Impact factor: 5.923

Review 10.  Putting the Brakes on Tumorigenesis with Natural Products of Plant Origin: Insights into the Molecular Mechanisms of Actions and Immune Targets for Bladder Cancer Treatment.

Authors:  Qiushuang Wu; Janet P C Wong; Hang Fai Kwok
Journal:  Cells       Date:  2020-05-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.